Leukemia Research
Volume 27, Issue 5 , Pages 437-444 , May 2003

Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells

  • Sepideh Shaker

      Affiliations

    • Centre de Recherche Pédiatrique, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine, Montréal, Quebec, Canada, H3T 1C5
    • ,
  • Mark Bernstein

      Affiliations

    • Département de Pharmacologie, Université de Montréal, and Service d’Hématologie-Oncologie, Montréal, Quebec, Canada, H3T 1C5
    • ,
  • Louise F Momparler

      Affiliations

    • Centre de Recherche Pédiatrique, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine, Montréal, Quebec, Canada, H3T 1C5
    • ,
  • Richard L Momparler

      Affiliations

    • Centre de Recherche Pédiatrique, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine, Montréal, Quebec, Canada, H3T 1C5
    • Corresponding Author InformationCorresponding author. Tel.: +1-514-345-4931; fax: +1-514-345-4801.

Received 30 May 2002 ,Accepted 28 September 2002.

References 

  1. Lotem J, Sachs L. Different blocks in differentiation of myeloid leukemia cells. Proc. Natl. Acad. Sci. U.S.A. 1974;71:3507–3511
  2. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 1983;62:709–721
  3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat. Genet. 1999;21:163–167
  4. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis. Trends Genet. 2000;16:168–174
  5. Momparler RL, Bovenzi V. DNA methylation and cancer. J. Cell Physiol. 2000;183:145–154
  6. Cameron EE, Kurtis E, Myöhänen BS, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999;21:103–107
  7. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, et al.  Loss of p73 gene expression in leukemia/lymphomas due to hypermethylation. Blood. 1999;94:1113–1120
  8. Liu M, Taketani T, Li R, Takita J, Taki T, Yang H, et al.  Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk. Res. 2001;25:441–447
  9. Pinto A, Attadia V, Fusco LA, Ferrara F, Spada OA, DiFiore P. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia. Blood. 1984;64:922–929
  10. Momparler RL, Doré BT, Momparler LF. Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Lett. 1990;54:21–28
  11. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin KT, et al.  Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk. Res. 1981;5:453–462
  12. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharma. Ther. 1985;30:277–286
  13. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br. J. Cancer. 1991;64:144–148
  14. Marks PA, Richom VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000;92:1210–1216
  15. Wolffe AP. Histone deacetylase: a regulator of transcription. Science. 1996;272:371–372
  16. Archer SY, Hoddin RA. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 1999;9:171–174
  17. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990;265:17174–17179
  18. Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, et al.  Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 1999;13:1316–1324
  19. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemic cells. Cancer Res. 1999;59:2766–2769
  20. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 2001;7:971–976
  21. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998;19:187–191
  22. Bovenzi V, Momparler RL. Antineoplastic action and expression of retinoic acid receptor β gene in breast carcinoma cells treated with 5-aza-2′-deoxycytidine and a histone deacetylase inhibitor. Cancer Chem. Pharmacol. 2001;48:71–76
  23. Nakajima H, Kim YB, Terano H, Yoshida M, Horinoushi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 1998;41:126–133
  24. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn LW, et al.  Depsipeptide (FR981228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 1999;94:1401–1408
  25. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al.  FR901228, a novel antitumor antibiotic bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiotics. 1994;47:315–323
  26. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386–389
  27. Lin KT, Momparler RL, Rivard GE. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J. Pharma. Sci. 1981;70:1228–1232
  28. Momparler RL. In vitro systems for evaluation of combination chemotherapy. Pharma. Ther. 1980;8:21–25
  29. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. New Engl. J. Med. 1999;341:1051–1062
  30. Flasshove M, Meusers P, Schutte J, Noppeney R, Beelen DW, Sohrab S, et al.  Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann. Hematol. 2000;79:533–542
  31. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1998;90:1621–1625
  32. Sacchi S, Kantarjian HM, O’Brien S, Cortes J, Rios MB, Giles FJ, et al.  Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632–2641
  33. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al.  Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000;18:956–962
  34. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-β-d-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk. Res. 1984;8:1043–1049
  35. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as possible mechanism of chemotherapeutic action. Cancer Res. 1983;43:3493–3496
  36. Momparler RL, Bouchard J, Onetto N, Rivard GE. 5-AZA-2′-deoxycytidine in patients with acute leukemia inhibits DNA methylation. Leuk. Res. 1984;8:181–185
  37. Rajgolikar G, Chan KK, Wang HR. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 1998;51:29–38
  38. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, et al.  Sequential 5-Aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 2001;24:151–161
  39. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J, et al.  Pilot phase I–II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 1997;8:358–368
  40. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp. Opin. Invest. Drugs 2000;9:2923–34.
  41. Momparler RL. Molecular cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharma. Ther. 1985;30:287–299

PII: S0145-2126(02)00222-9

doi: 10.1016/S0145-2126(02)00222-9

Leukemia Research
Volume 27, Issue 5 , Pages 437-444 , May 2003

Article Tools

* Image Usage & Resolution